The Potential Role of Long-Acting Injectable Antipsychotics in People With Schizophrenia and Comorbid Substance Use

REFERENCES

• Adams , C. E. , Fenton , M. K. , Quraishi , S. and David , A. S. 2001 . Systematic meta-review of depot antipsychotic drugs for people with schizophrenia . The British Journal of Psychiatry , 179 : 290 – 299 .
   PubMed Web of Science ®Google Scholar
• Adrian , M. and Barry , S. J. 2003 . Physical and mental health problems associated with the use of alcohol and drugs . Substance Use & Misuse , 38 ( 11–13 ) : 1575 – 1614 .
   PubMed Web of Science ®Google Scholar
• Ananth , J. , Vandewater , S. , Kamal , M. , Brodsky , A. , Gamal , R. and Miller , M. 1989 . Mixed diagnosis of substance abuse in psychiatric patients . Hospital and Community Psychiatry , 40 : 297 – 299 .
   PubMedGoogle Scholar
• Arango , C. , Bombín , I. , González-Salvador , T. , García-Cabeza , I. and Bobes , J. 2006 . Randomised clinical trial comparing oral versus depot formulations of zuclopenthixol in patients with schizophrenia and previous violence . European Psychiatry , 21 ( 1 ) : 34 – 40 .
   PubMedGoogle Scholar
• Becker , M. A. , Young , M. S. , Ochshorn , E. and Diamond , R. J. 2007 . The relationship of antipsychotic medication class and adherence with treatment outcomes and costs for Florida Medicaid beneficiaries with schizophrenia . Administration & Policy in Mental Health , 34 ( 3 ) : 307 – 314 .
   PubMedGoogle Scholar
• Bellack , A. S. , Morrison , R. L. , Wixted , J. T. and Mueser , K. T. 1990 . An analysis of social competence in schizophrenia . The British Journal of Psychiatry , 156 : 809 – 818 .
   PubMed Web of Science ®Google Scholar
• Bellack , A. S. , Bennett , M. E. , Gearon , J. S. , Brown , C. H. and Yang , Y. 2006 . A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness . Archives of General Psychiatry , 63 ( 4 ) : 426 – 432 .
   PubMed Web of Science ®Google Scholar
• Beresford , T. P. , Clapp , L. , Martin , B. , Wiberg , J. L. , Alfers , J. and Beresford , H. F. 2005 . Aripiprazole in schizophrenia with cocaine dependence: A pilot study . Journal of Clinical Psychopharmacology , 25 ( 4 ) : 363 – 366 .
   PubMed Web of Science ®Google Scholar
• Bowers , M. B. and Swigar , M. E. 1983 . Vulnerability to psychosis associated with hallucinogen use . Psychiatry Research , 9 : 91 – 97 .
   PubMed Web of Science ®Google Scholar
• Brady , K. T. , Anton , R. , Ballenger , J. C. , Lydiard , R. B. , Adinoff , B. and Selander , J. 1990 . Cocaine abuse among schizophrenic patients . American Journal of Psychiatry , 147 : 1164 – 1167 .
   PubMed Web of Science ®Google Scholar
• Brown , E. S. , Nejtek , V. A. , Perantie , D. C. , Rajan Thomas , N. and Rush , A. J. 2003 . Cocaine and amphetamine use in patients with psychiatric illness: A randomized trial of typical antipsychotic continuation or discontinuation . Journal of Clinical Psychopharmacology , 23 ( 4 ) : 384 – 388 .
   PubMed Web of Science ®Google Scholar
• Brown , E. S. , Jeffress , J. , Liggin , J. D. , Garza , M. and Beard , L. 2005 . Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole . Journal of Clinical Psychiatry , 66 ( 6 ) : 756 – 760 .
   PubMed Web of Science ®Google Scholar
• Brunette , M. F. , Mueser , K. T. and Drake , R. E. 2004 . A review of research on residential programs for people with severe mental illness and co-occurring substance use disorders . Drug and Alcohol Review , 23 ( 4 ) : 471 – 481 .
   PubMed Web of Science ®Google Scholar
• Buchanan , R. W. , Kreyenbuhl , J. , Kelly , D. L. , Noel , J. M. , Boggs , D. L. , Fischer , B. A. and Keller , W. 2010 . Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements . Schizophrenia Bulletin , 36 ( 1 ) : 71 – 93 .
   PubMed Web of Science ®Google Scholar
• Bush , C. T. , Langford , M. W. , Rosen , P. and Gott , W. 1990 . Operation outreach: Intensive case management for severely psychiatrically disabled adults . Hospital & Community Psychiatry , 41 ( 6 ) : 647 – 649 .
   PubMedGoogle Scholar
• Byerly , M. J. , Nakonezny , P. A. and Lescouflair , E. 2007 . Antipsychotic medication adherence in schizophrenia . Psychiatric Clinics of North America , 30 : 437 – 452 .
   PubMed Web of Science ®Google Scholar
• Cantor-Graee , E. , Nordstrom , L. G. and McNeil , T. F. 2001 . Substance abuse in schizophrenia: A review of the literature and a study of correlates in Sweden . Schizophrenia Research , 48 : 69 – 82 .
   PubMed Web of Science ®Google Scholar
• Chambers , R. A. , Krystal , J. H. and Self , D. W. 2001 . A neurobiological basis for substance abuse comorbidity in schizophrenia . Biological Psychiatry , 50 : 71 – 83 .
   PubMed Web of Science ®Google Scholar
• Chouljian , T. L. , Shumway , M. and Balanzio , E. 1995 . Substance use among schizophrenia outpatients: Prevalence, course and relation to financial status . Annals of Clinical Psychiatry , 7 : 19 – 24 .
   PubMedGoogle Scholar
• Cleghorn , J. M. , Kaplan , R. D. , Szechtman , B. , Szechtman , H. , Brown , G. M. and Franco , S. 1991 . Substance abuse and schizophrenia: Effect on symptoms but not neurocognitive function . Journal of Clinical Psychiatry , 52 : 26 – 30 .
   PubMed Web of Science ®Google Scholar
• Conley , R. R. , Kelly , D. L. and Gale , E. A. 1998 . Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse . Schizophrenia Research , 33 ( 1–2 ) : 95 – 101 .
   PubMed Web of Science ®Google Scholar
• del Giudice , J. , Clark , W. G. and Gocka , E. F. 1975 . Prevention of recidivism of schizophrenics treated with fluphenazine enanthate . Psychosomatics , 16 ( 1 ) : 32 – 36 .
   PubMedGoogle Scholar
• Dickey , B. and Azeni , H. 1996 . Persons with dual diagnoses of substance abuse and major mental illness: Their excess costs of psychiatric care . American Journal of Public Health , 86 : 973 – 977 .
   PubMed Web of Science ®Google Scholar
• Dickey , B. , Normand , S. L. , Weiss , R. D. , Drake , R. E. and Azeni , H. 2002 . Medical morbidity, mental illness, and substance use disorders . Psychiatric Services , 53 ( 7 ) : 861 – 867 .
   PubMed Web of Science ®Google Scholar
• Dixon , L. , Haas , G. , Weiden , P. J. , Sweeney , J. and Frances , A. J. 1991 . Drug abuse in schizophrenic patients: Clinical correlates and reasons for use . American Journal of Psychiatry , 148 : 224 – 230 .
   PubMed Web of Science ®Google Scholar
• Dixon , L. 1999 . Dual diagnosis of substance abuse in schizophrenia: Prevalence and impact on outcomes . Schizophrenia Research , 35 : 93 – 100 .
   PubMed Web of Science ®Google Scholar
• Dixon , L. B. , Dickerson , F. , Bellack , A. S. , Bennett , M. , Dickinson , D. , Goldberg , R. W. and Kreyenbuhl , J. 2010 . Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements . Schizophrenia Bulletin , 36 ( 1 ) : 48 – 70 .
   PubMed Web of Science ®Google Scholar
• Drake , R. E. , Osher , F. C. and Wallach , M. A. 1989 . Alcohol use and abuse in schizophrenia: A prospective community study . Journal of Nervous and Mental Disease , 177 : 408 – 414 .
   PubMed Web of Science ®Google Scholar
• Drake , R. E. , Osher , F. C. , Noordsy , D. L. , Hurlbut , S. C. , Teague , G. B. and Beaudett , M. S. 1990 . Diagnosis of alcohol use disorders in schizophrenia . Schizophrenia Bulletin , 16 : 57 – 67 .
   PubMed Web of Science ®Google Scholar
• Drake , R. E. and Wallach , M. A. 1993 . Moderate drinking among people with severe mental illness . Hospital and Community Psychiatry , 44 : 780 – 782 .
   PubMedGoogle Scholar
• Drake , R. E. , Rosenberg , S. D. and Mueser , K. T. 1996 . Assessing substance use disorder in persons with severe mental illness . New Directions for Mental Health Services , : 3 – 17 .
   PubMedGoogle Scholar
• Drake , R. E. , O’Neal , E. L. and Wallach , M. A. 2008 . A systematic review of psychosocial research on psychosocial interventions for people with co-occurring severe mental and substance use disorders . Journal of Substance Abuse Treatment , 34 ( 1 ) : 123 – 138 .
   PubMed Web of Science ®Google Scholar
• Drebing , C. E. , Van Ormer , E. A. , Krebs , C. , Rosenheck , R. , Rounsaville , B. , Herz , L. and Penk , W. 2005 . The impact of enhanced incentives on vocational rehabilitation outcomes for dually diagnosed veterans . Journal of Applied Behavior Analysis , 38 ( 3 ) : 359 – 372 .
   PubMedGoogle Scholar
• Fenton , W. S. , Blyler , C. R. and Heinssen , R. K. 1997 . Determinants of medication compliance in schizophrenia: Empirical and clinical findings . Schizophrenia Bulletin , 23 : 637 – 651 .
   PubMed Web of Science ®Google Scholar
• Fleischhacker , W. W. 2009 . Second-generation antipsychotic long-acting injections: Systematic review . British Journal of Psychiatry Supplement , 52 : S29 – S36 .
   PubMedGoogle Scholar
• Fowler , I. L. , Carr , V. J. , Carter , N. T. and Lewin , T. J. 1998 . Patterns of current and lifetime substance use in schizophrenia . Schizophrenia Bulletin , 24 : 443 – 455 .
   PubMed Web of Science ®Google Scholar
• Frisher , M. , Collins , J. , Millson , D. , Crome , I. and Croft , P. J. 2004 . Prevalence of comorbid psychiatric illness and substance misuse in primary care in England and Wales . Journal of Epidemiology & Community Health , 58 ( 12 ) : 1036 – 1041 .
   PubMed Web of Science ®Google Scholar
• Gilmer , T. P. , Dolder , C. R. , Lacro , J. P. , Folsom , D. P. , Lindamer , L. , Garcia , P. and Jeste , D. V. 2004 . Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia . American Journal of Psychiatry , 161 ( 4 ) : 692 – 699 .
   PubMed Web of Science ®Google Scholar
• Gitlin , M. J. , Midha , K. K. , Fogelson , D. and Nuechterlein , K. 1988 . Persistence of fluphenazine in plasma after decanoate withdrawal . Journal of Clinical Psychopharmacology , 8 ( 1 ) : 53 – 56 .
   PubMedGoogle Scholar
• Goodman , L. A. , Salyers , M. P. , Mueser , K. T. , Rosenberg , S. D. , Swartz , M. , Essock , S. M. and Swanson , J. 2001 . Recent victimization in women and men with severe mental illness: Prevalence and correlates . Journal of Traumatic Stress , 14 : 615 – 632 .
   PubMed Web of Science ®Google Scholar
• Green , A. I. , Zimmet , S. V. , Strouss , R. D. and Schildkraut , J. J. 1999 . Clozapine for comorbid substance use disorder and schizophrenia: Do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? . Harvard Review of Psychiatry , 6 : 287 – 296 .
   PubMed Web of Science ®Google Scholar
• Green , A. I. , Tohen , M. F. , Hamer , R. M. , Strakowski , S. M. , Lieberman , J. A. , Glick , I. and … HGDH Research Group . 2004 . First episode schizophrenia-related psychosis and substance use disorders: Acute response to olanzapine and haloperidol . Schizophrenia Research , 66 : 125 – 135 .
   PubMed Web of Science ®Google Scholar
• Green , A. I. 2005 . Schizophrenia and comorbid substance use disorder: Effects of antipsychotics . Journal of Clinical Psychiatry , 66 ( Supplement 6 ) : 21 – 26 .
   PubMedGoogle Scholar
• Haddad , P. M. , Taylor , M. and Niaz , O. S. 2009 . First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: Systematic review of randomised controlled trials and observational studies . British Journal of Psychiatry , 195 : S20 – S28 .
   Web of Science ®Google Scholar
• Haddock , G. , Barrowclough , C. , Tarrier , N. , Moring , J. , O’Brien , R. , Schofield , N. and Lewis , S. 2003 . Cognitive-behavioural therapy and motivational intervention for schizophrenia and substance misuse. 18-month outcomes of a randomised controlled trial . British Journal of Psychiatry , 183 : 418 – 426 .
   PubMed Web of Science ®Google Scholar
• Hambrecht , M. and Hafner , H. 1996 . Substance abuse and the onset of schizophrenia . Biological Psychiatry , 40 : 1155 – 1163 .
   PubMed Web of Science ®Google Scholar
• Hiday , V. A. , Swartz , M. S. , Swanson , J. W. , Borum , R. and Wagner , H. R. 1999 . Criminal victimization of persons with severe mental illness . Psychiatric Services , 50 : 62 – 68 .
   PubMed Web of Science ®Google Scholar
• Hoff , R. A. and Rosenheck , R. A. 1999 . The cost of treating substance abuse patients with and without comorbid psychiatric disorders . Psychiatric Services , 50 : 1309 – 1315 .
   PubMed Web of Science ®Google Scholar
• Hogarty , G. E. , Schooler , N. R. , Ulrich , R. , Mussare , F. , Ferro , P. and Herron , E. 1979 . Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride . Archives of General Psychiatry , 36 ( 12 ) : 1283 – 1294 .
   PubMedGoogle Scholar
• Hough , D. , Gopal , S. , Vijapurkar , U. , Lim , P. , Morozova , M. and Eerdekens , M. 2010 . Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled study . Schizophrenia Research , 116 : 107 – 117 .
   PubMed Web of Science ®Google Scholar
• Hunt , G. E. , Bergen , J. and Bashir , M. 2002 . Medication compliance and comorbid substance abuse in schizophrenia: Impact on community survival 4 years after a relapse . Schizophrenia Research , 54 : 253 – 264 .
   PubMed Web of Science ®Google Scholar
• Kane , J. M. , Eerdekens , M. , Lindenmayer , J. P. , Keith , S. J. , Lesem , M. and Karcher , K. 2003 . Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotic . American Journal of Psychiatry , 160 ( 6 ) : 1125 – 1132 .
   PubMed Web of Science ®Google Scholar
• Kane , J. M. , Detke , H. C. , Naber , D. , Sethuraman , G. , Lin , D. Y. , Bergstrom , R. F. and McDonnell , D. 2010 . Olanzapine long-acting injection: A 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia . American Journal of Psychiatry , 167 ( 2 ) : 181 – 189 .
   PubMed Web of Science ®Google Scholar
• Kavanagh , D. J. , McGrath , J. J. and Jenner , L. 2000 . Substance use in psychotic disorders: Results from the Australian survey of mental health and wellbeing [abstract] . Acta Psychiatrica Scandinavica , 102 ( Suppl. 404 ) : 5
   Google Scholar
• Kavanagh , D. J. , McGrath , J. , Saunders , J. B. , Dore , G. and Clark , D. 2002 . Substance misuse in patients with schizophrenia: Epidemiology and management . Drugs , 62 ( 5 ) : 743 – 755 .
   PubMed Web of Science ®Google Scholar
• Kelly , D. L. , Gale , E. A. and Conley , R. R. 2003 . Clozapine treatment in patients with prior substance abuse . Canadian Journal of Psychiatry , 48 ( 2 ) : 111 – 114 .
   PubMedGoogle Scholar
• Kelly , T. M. , Daley , D. C. and Douaihy , A. B. 2012 . Treatment of substance abusing patients with comorbid psychiatric disorders . Addictive Behaviors , 37 ( 1 ) : 11 – 24 .
   PubMed Web of Science ®Google Scholar
• Kramer , M. , Litman , R. , Hough , D. , Lane , R. , Lim , P. , Liu , Y. and Eerdekens , M. 2010 . Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study . The International Journal of Neuropsychopharmacology , 13 ( 5 ) : 635 – 647 .
   PubMed Web of Science ®Google Scholar
• Kreyenbuhl , J. , Slade , E. P. , Medoff , D. R. , Brown , C. H. , Ehrenreich , B. , Afful , J. and Dixon , L. B. 2011 . Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia . Schizophrenia Research , 131 ( 1–3 ) : 127 – 132 .
   PubMed Web of Science ®Google Scholar
• Lacro , J. P. , Dunn , L. B. , Dolder , C. R. , Leckban , S. G. and Jeste , D. V. 2002 . Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature . Journal of Clinical Psychiatry , 63 : 892 – 909 .
   PubMed Web of Science ®Google Scholar
• Lambert , M. , Conus , P. , Lubman , D. I. , Wade , D. , Yuen , H. , Moritz , S. and Schimmelmann , B. G. 2005 . The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis . Acta Psychiatrica Scandinavica , 112 : 141 – 148 .
   PubMed Web of Science ®Google Scholar
• Lauriello , J. , Lambert , T. , Andersen , S. , Lin , D. , Taylor , C. C. and McDonnell , D. 2008 . An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia . The Journal of Clinical Psychiatry , 69 ( 5 ) : 790 – 799 .
   PubMed Web of Science ®Google Scholar
• Leucht , C. , Heres , S. , Kane , J. M. , Kissling , W. , Davis , J. M. and Leucht , S. 2011 . Oral versus depot antipsychotic drugs for schizophrenia—A critical systematic review and meta-analysis of randomised long-term trials . Schizophrenia Research , 127 ( 1–3 ) : 83 – 92 .
   PubMed Web of Science ®Google Scholar
• Levin , F. R. , Evans , S. M. , Kumaraswamy , S. , Collins , E. D. , Regent , N. and Kleber , H. D. 1998 . Fluphenazine treatment for cocaine abusers with schizophrenia: A pilot study . American Journal of Drug and Alcohol Abuse , 24 : 343 – 360 .
   PubMed Web of Science ®Google Scholar
• Liberman , R. P. , Lillie , F. , Falloon , I. R. , Harpin , R. E. , Hutchinson , W. and Stoute , B. 1984 . Social skills training with relapsing schizophrenics. An experimental analysis . Behavior Modification , 8 ( 2 ) : 155 – 179 .
   PubMedGoogle Scholar
• Lindenmayer , J. 2010 . Long-acting injectable antipsychotics: Focus on olanzapine pamoate . Journal of Neuropsychiatric Disease and Treatment , 6 : 261 – 267 .
   PubMed Web of Science ®Google Scholar
• Littrell , K. H. , Petty , R. G. , Hilligoss , N. M. , Peabody , C. D. and Johnson , C. G. 2001 . Olanzapine treatment for patients with schizophrenia and substance abuse . Journal of Substance Abuse Treatment , 21 ( 4 ) : 217 – 221 .
   PubMed Web of Science ®Google Scholar
• Longo , L. P. 2002 . Olanzapine for cocaine craving and relapse prevention in 2 patients . Journal of Clinical Psychiatry , 63 ( 7 ) : 595 – 596 .
   PubMedGoogle Scholar
• Margolese , H. C. , Malchy , L. , Negrete , J. C. , Tempier , R. and Gill , K. 2004 . Drug and alcohol use among patients with schizophrenia and related psychoses: Levels and consequences . Schizophrenia Research , 67 : 157 – 166 .
   PubMed Web of Science ®Google Scholar
• McEvoy , J. P. , Freudenreich , O. , Levin , E. D. and Rose , J. E. 1995 . Haloperidol increases smoking in patients with schizophrenia . Journal of Psychopharmacology , 119 : 124 – 126 .
   Web of Science ®Google Scholar
• McFarlane , W. R. , Dixon , L. , Lukens , E. and Lucksted , A. 2003 . Family psychoeducation and schizophrenia: A review of the literature . Journal of Marital and Family Therapy , 29 ( 2 ) : 223 – 245 .
   PubMed Web of Science ®Google Scholar
• Miles , H. and Johnson , S. 2003 . Characteristics of subgroups of individuals with psychotic illness and a comorbid substance use disorder . Psychiatric Services , 54 : 554 – 561 .
   PubMed Web of Science ®Google Scholar
• Morrison , R. L. , Bellack , A. S. and Mueser , K. T. 1988 . Deficits in facial-affect recognition and schizophrenia . Schizophrenia Bulletin , 14 : 67 – 83 .
   PubMed Web of Science ®Google Scholar
• Mueser , K. T. , Yarnold , P. R. , Levinson , D. F. , Singh , H. , Bellack , A. S. , Lee , K. and Yadalam , K. G. 1990 . Prevalence of substance abuse in schizophrenia: Demographic and clinical correlates . Schizophrenia Bulletin , 16 : 31 – 56 .
   PubMed Web of Science ®Google Scholar
• Mueser , K. T. , Yarnold , P. R. , Rosenberg , S. D. , Swett , C. Jr. , Miles , K. M. and Hill , D. 2000 . Substance use disorder in hospitalized severely mentally ill psychiatric patients: Prevalence, correlates, and subgroups . Schizophrenia Bulletin , 26 : 179 – 192 .
   PubMed Web of Science ®Google Scholar
• Norman , R. M. and Malla , A. K. 2002 . Examining adherence to medication and substance use as possible confounds of duration of untreated psychosis . The Journal of Nervous and Mental Disease , 190 : 331 – 334 .
   PubMed Web of Science ®Google Scholar
• Nuechterlein , K. H. and Dawson , M. E. 1984 . Information processing and attentional functioning in the developmental course of schizophrenic disorders . Schizophrenia Bulletin , 10 : 160 – 203 .
   PubMed Web of Science ®Google Scholar
• Nyberg , S. , Farde , L. and Halldin , C. 1997 . Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Preliminary findings . Archives of General Psychiatry , 54 ( 10 ) : 953 – 958 .
   PubMedGoogle Scholar
• Olfson , M. , Mechanic , D. , Hansell , S. , Boyer , C. A. , Walkup , J. and Weiden , P. J. 2000 . Predicting medication noncompliance after hospital discharge among patients with schizophrenia . Psychiatric Services , 51 : 216 – 222 .
   PubMed Web of Science ®Google Scholar
• Olivera , A. A. , Kiefer , M. W. and Manley , N. K. 1990 . Tardive dyskinesia in psychiatric patients with substance abuse . American Journal of Drug and Alcohol Abuse , 16 : 57 – 66 .
   PubMed Web of Science ®Google Scholar
• Owen , R. R. , Fischer , E. P. , Booth , B. M. and Cuffel , B. J. 1996 . Medication noncompliance and substance abuse among patients with schizophrenia . Psychiatric Services , 47 : 853 – 858 .
   PubMed Web of Science ®Google Scholar
• Perkins , D. O. 2002 . Predictors of noncompliance in patients with schizophrenia . Journal of Clinical Psychiatry , 63 : 1121 – 1128 .
   PubMed Web of Science ®Google Scholar
• Perkins , D. O. , Gu , H. , Weiden , P. J. , McEvoy , J. P. , Hamer , R. M. and Lieberman , J. A. 2008 . Comparison of Atypicals in First Episode study group. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: A randomized, double-blind, flexible-dose, multicenter study . Journal of Clinical Psychiatry , 69 ( 1 ) : 106 – 113 .
   PubMed Web of Science ®Google Scholar
• Potvin , S. , Stip , E. and Roy , J. Y. 2003 . Clozapine, quetiapine, and olanzapine among addicted schizophrenic patients: Towards testable hypothesis . International Clinical Psychopharmacology , 18 ( 3 ) : 121 – 132 .
   PubMedGoogle Scholar
• Potvin , S. , Stip , E. , Lipp , O. , Elie , R. , Mancini-Marië , A. , Demers , M. F. and Gendron , A. 2006 . Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: An open-label trial . Current Medical Research & Opinion , 22 ( 7 ) : 1277 – 1285 .
   PubMed Web of Science ®Google Scholar
• Pristach , C. A. and Smith , C. M. 1990 . Medication compliance and substance abuse among schizophrenia patients . Hospital and Community Psychiatry , 41 : 1345 – 1348 .
   PubMedGoogle Scholar
• Ries , R. K. , Dyck , D. G. , Short , R. , Srebnik , D. , Fisher , A. and Comtois , K. A. 2004 . Outcomes of managing disability benefits among patients with substance dependence and severe mental illness . Psychiatric Services , 55 ( 4 ) : 445 – 447 .
   PubMedGoogle Scholar
• Regier , D. A. , Farmer , M. E. , Rae , D. S. , Locke , B. Z. , Keith , S. J. , Judd , L. L. and Goodwin , F. K. 1990 . Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiological Catchment Area (ECA) study . The Journal of American Medical Association , 264 : 2511 – 2518 .
   PubMed Web of Science ®Google Scholar
• Rifkin , A. , Quitkin , F. , Rabiner , C. J. and Klein , D. F. 1977 . Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year . Archives of General Psychiatry , 34 ( 1 ) : 43 – 47 .
   PubMedGoogle Scholar
• Rosenheck , R. A. , Krystal , J. H. , Lew , R. , Barnett , P. G. , Fiore , L. , Valley , D. and … CSP555 Research Group . 2011 . Long-acting risperidone and oral antipsychotics in unstable schizophrenia . The New England Journal of Medicine , 364 ( 9 ) : 842 – 851 .
   PubMed Web of Science ®Google Scholar
• Rubio , G. , Martinez , I. , Ponce , G. , Jimenez-Arriero , M. A. , Lopez-Munoz , F. and Alamo , C. 2006 . Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity . Canadian Journal of Psychiatry , 51 : 531 – 539 .
   PubMed Web of Science ®Google Scholar
• Schneier , F. R. and Siris , S. G. 1987 . A review of psychoactive substance use and abuse in schizophrenia. Patterns of drug choice . The Journal of Nervous and Mental Disease , 175 : 641 – 652 .
   PubMed Web of Science ®Google Scholar
• Schooler , N. R. , Levine , J. , Severe , J. B. , Brauzer , B. , DiMascio , A. , Klerman , G. L. and Tuason , V. B. 1980 . Prevention of relapse in schizophrenia. An evaluation of fluphenazine decanoate . Archives of General Psychiatry , 37 ( 1 ) : 16 – 24 .
   PubMedGoogle Scholar
• Schooler , N. R. 2003 . Relapse and rehospitalization: Comparing oral and depot antipsychotics . Journal of Clinical Psychiatry , 64 ( Suppl. 16 ) : 14 – 17 .
   PubMed Web of Science ®Google Scholar
• Sevy , S. , Robinson , D. G. , Sunday , S. , Napolitano , B. , Miller , R. , McCormack , J. and Kane , J. 2011 . Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes . Psychiatry Research , 188 ( 3 ) : 310 – 314 .
   PubMedGoogle Scholar
• Simpson , G. M. , Mahmoud , R. A. , Lasser , R. A. , Kujawa , M. , Bossie , C. A. , Turkoz , I. and Gharabawi , G. M. 2006 . A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder . The Journal of Clinical Psychiatry , 67 ( 8 ) : 1194 – 1203 .
   PubMedGoogle Scholar
• Siris , S. G. 1990 . Pharmacological treatment of substance-abusing schizophrenic patients . Schizophrenia Bulletin , 16 : 111 – 122 .
   PubMed Web of Science ®Google Scholar
• Siris , S. G. , Kane , J. M. , Frechen , K. , Sellew , A. P. , Mandeli , J. and Fasano-Dube , B. 1988 . Histories of substance abuse in patients with postpsychotic depressions . Comprehensive Psychiatry , 29 ( 6 ) : 550 – 557 .
   PubMed Web of Science ®Google Scholar
• Smelson , D. A. , Losonczy , M. F. , Davis , C. W. , Kaune , M. , Williams , J. and Ziedonis , D. 2002 . Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence . Canadian Journal of Psychiatry , 47 : 671 – 675 .
   PubMed Web of Science ®Google Scholar
• Soyka , M. , Albus , M. , Kathmann , N. , Finelli , A. , Hofstetter , S. , Holzbach , R. and Sand , P. 1993 . Prevalence of alcohol and drug abuse in schizophrenic inpatients . European Archives of Psychiatry and Clinical Neuroscience , 242 : 272 – 362 .
   Google Scholar
• Soyka , M. and Sand , P. 1995 . Successful treatment with flupenthixol decanoate of a patient with both schizophrenia and alcoholism . Pharmacopsychiatry , 28 ( 2 ) : 64 – 65 .
   PubMedGoogle Scholar
• Soyka , M. 2000a . Alcoholism and schizophrenia . Addiction , 95 : 1613 – 1618 .
   PubMed Web of Science ®Google Scholar
• Soyka , M. 2000b . Substance abuse, psychiatric disorder, and disturbed behavior . British Journal of Psychiatry , 176 : 345 – 350 .
   PubMed Web of Science ®Google Scholar
• Soyka , M. , Aichmuller , C. , von Bardeleben , U. , Beneke , M. , Glaser , T. , Hornung-Knobel , S. and Wegner , U. 2003 . Flupenthixol in relapse prevention in schizophrenics with comorbid alcoholism: Results from an open clinical study . European Addiction Research , 9 : 65 – 72 .
   PubMed Web of Science ®Google Scholar
• Stein , L. I. and Test , M. A. 1980 . Alternative to mental hospital treatment. I. Conceptual model, treatment program, and clinical evaluation . Archives of General Psychiatry , 37 ( 4 ) : 392 – 397 .
   PubMed Web of Science ®Google Scholar
• Swadi , H. and Bobier , C. 2003 . Substance use disorders comorbidity among inpatient youths with psychiatric disorder . Australian and New Zealand Journal of Psychiatry , 37 : 294 – 298 .
   PubMed Web of Science ®Google Scholar
• Swartz , M. S. , Wagner , H. R. , Swanson , J. W. , Stroup , T. S. , McEvoy , J. P. , Canive , J. M. and Lieberman , J. A. 2006 . Baseline prevalence and correlates from the NIMH CATIE study . The Journal of Nervous and Mental Disease , 194 : 164 – 172 .
   PubMed Web of Science ®Google Scholar
• Swofford , C. D. , Kasckow , J. W. , Scheeler-Gilkey , G. and Inderbitzin , L. B. 1996 . Substance use: A powerful predictor of relapse in schizophrenia . Schizophrenia Research , 20 : 145 – 151 .
   PubMed Web of Science ®Google Scholar
• Swofford , C. D. , Scheller-Gilkey , G. , Miller , A. H. , Woolwine , B. and Mance , R. 2000 . Double jeopardy: Schizophrenia and substance abuse . American Journal of Drug and Alcohol Abuse , 26 ( 3 ) : 343 – 353 .
   PubMed Web of Science ®Google Scholar
• Tegeler , J. and Lehmann , E. 1981 . A follow-up study of schizophrenic outpatients treated with depot-neuroleptics . Progress in Neuropsychopharmacology , 5 ( 1 ) : 79 – 90 .
   PubMedGoogle Scholar
• Tiihonen , J. , Haukka , J. , Taylor , M. , Haddad , P. M. , Patel , M. X. and Korhonen , P. 2011 . A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia . The American Journal of Psychiatry , 168 ( 6 ) : 603 – 609 .
   PubMed Web of Science ®Google Scholar
• Tsuang , J. , Marder , S. R. , Han , A. and Hsieh , W. 2002 . Olanzapine treatment for patients with schizophrenia and cocaine abuse . Journal of Clinical Psychiatry , 63 ( 12 ) : 1180 – 1181 .
   PubMedGoogle Scholar
• Tsuang , J. and Fong , T. W. 2004 . Treatment of patients with schizophrenia and substance abuse disorders . Current Pharmaceutical Design , 10 ( 18 ) : 2249 – 2261 .
   PubMed Web of Science ®Google Scholar
• Valenstein , M. , Ganoczy , D. , McCarthy , J. F. , Myra Kim , H. , Lee , T. A. and Blow , F. C. 2006 . Antipsychotic adherence over time among patients receiving treatment for schizophrenia: A retrospective review . Journal of Clinical Psychiatry , 67 : 1542 – 1550 .
   PubMed Web of Science ®Google Scholar
• Van Mastrigt , S. , Addington , J. and Addington , D. 2004 . Substance misuse at presentation to an early psychosis program . Social Psychiatry and Psychiatric Epidemiology , 39 : 69 – 72 .
   PubMed Web of Science ®Google Scholar
• Velligan , D. I. , Wang , M. , Diamond , P. , Glahn , D. C. , Castillo , D. , Bendle , S. and Miller , A. L. 2007 . Relationships among subjective and objective measures of adherence to oral antipsychotic medications . Psychiatric Services , 58 ( 9 ) : 1187 – 1192 .
   PubMed Web of Science ®Google Scholar
• Wade , D. , Harrigan , S. , Edwards , J. , Burgess , P. M. , Whelan , G. and McGorry , P. D. 2006 . Substance misuse in first-episode psychosis: 15-month prospective follow-up study . British Journal of Psychiatry , 189 : 229 – 234 .
   PubMed Web of Science ®Google Scholar
• Weiden , P. , Rapkin , B. , Zygmunt , A. , Mott , T. , Goldman , D. and Frances , A. 1995 . Post discharge medication compliance of inpatients converted from an oral depot neuroleptic regimen . Psychiatric Services , 46 : 1049 – 1054 .
   PubMed Web of Science ®Google Scholar
• Weiss , R. D. , Griffin , M. L. , Kolodziej , M. E. , Greenfield , S. F. , Najavits , L. M. , Daley , D. C. and Hennen , J. A. 2007 . A randomized trial of integrated group therapy versus group drug counseling for patients with bipolar disorder and substance dependence . American Journal of Psychiatry , 164 ( 1 ) : 100 – 107 .
   PubMed Web of Science ®Google Scholar
• Wilk , J. , Marcus , S. C. , West , J. , Countis , L. , Hall , R. , Regier , D. A. and Olfson , M. 2006 . Substance abuse and the management of medication nonadherence in schizophrenia . The Journal of Nervous and Mental Disease , 194 : 454 – 457 .
   PubMed Web of Science ®Google Scholar
• Wistedt , B. , Wiles , D. and Kolakowska , T. 1981 . Slow decline of plasma drug and prolactin levels after discontinuation of chronic treatment with depot neuroleptics . Lancet , 1 ( 8230 ) : 1163
   PubMedGoogle Scholar
• Wobrock , T. , Pajonk , F. G. , D’Amelio , R. and Falkai , P. 2005 . Schizophrenia and addiction . Psychoneuroendocrinology , 31 ( 9 ) : 433 – 440 .
   Google Scholar
• Wobrock , T. and Soyka , M. 2008 . Pharmacotherapy of schizophrenia with comorbid substance use disorder—reviewing the evidence and clinical recommendations . Progress in Neuro-psychopharmacology & Biological Psychiatry , 32 ( 6 ) : 1375 – 1385 .
   PubMed Web of Science ®Google Scholar
• Ziedonis , D. M. 2004 . Integrated treatment of co-occurring mental illness and addiction: Clinical intervention, program, and system perspectives . CNS Spectrums , 9 ( 12 ) : 892 – 904 . 925
   PubMed Web of Science ®Google Scholar
• Zimmet , S. V. , Strous , R. D. , Burgess , E. S. , Kohnstamm , S. and Green , A. I. 2000 . Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: A retrospective survey . Journal of Clinical Psychopharmacology , 20 ( 1 ) : 94 – 98 .
   PubMed Web of Science ®Google Scholar